Ahmad Nanaa

Internal Medicine

1901 W Harrison St
Chicago, IL 60612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

The Association of Social and Biological Factors with Clinical Outcomes in Patients with Lung Cancer and DNA Damage Repair Pathway Mutations: A Single-Institution Experience.

The Association of Social and Biological Factors with Clinical Outcomes in Patients with Lung Cancer and DNA Damage Repair Pathway Mutations: A Single-Institution Experience.

Journal: Cancers

Published: June 27, 2026

Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms.

Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms.

Journal: Hematological oncology

Published: April 22, 2025

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots.

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots.

Journal: Hematology reports

Published: March 21, 2025

Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience.

Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience.

Journal: Annals of hematology

Published: February 04, 2024

Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.

Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.

Journal: Haematologica

Published: January 06, 2024

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Blood cancer journal

Published: January 02, 2024

Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.

Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.

Journal: British journal of haematology

Published: July 26, 2023

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.

Journal: Blood cancer journal

Published: June 29, 2023

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.

Journal: Haematologica

Published: February 01, 2023

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.

Journal: Blood cancer journal

Published: November 24, 2022

Perioperative Management of Antiplatelet Therapy: A Systematic Review and Meta-analysis.

Perioperative Management of Antiplatelet Therapy: A Systematic Review and Meta-analysis.

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes

Published: October 28, 2022

Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.

Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.

Journal: Annals of hematology

Published: October 11, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026